2023-08-30 13:07:07 ET
Cannabis stocks rallied midday Wednesday amid reports that the US government was moving to reclassify the drug to a much lower risk category under the Controlled Substances Act.
Earlier Wednesday, Bloomberg reported that the US Department of Health and Human Services had sent a letter to the US Drug Enforcement Administration recommending that cannabis be reclassified from a Schedule I to a Schedule III drug.
Schedule I drugs are considered to have a high potential for abuse with no currently accepted medical use. The category includes drugs such as heroin and LSD. Schedule III drugs are defined has having low risk for psychological or physical dependence. Schedule III drugs include Tylenol with codeine, ketamine and anabolic steroids, according to the DEA’s website.
Stocks getting a boost from the news were Tilray ( NASDAQ: TLRY ), Canopy Growth ( NASDAQ: CGC ), Aurora Cannabis ( ACB ), Cronos ( CRON ), Village Farms ( VFF ), Curaleaf ( OTCPK:CURLF ), SNDL ( SNDL ) and Medical Marijuana ( OTCPK:MJNA ).
More on Tilray
- The Bullish Case For Tilray Brands
- Tilray: European Movement To Legalize Cannabis Can Accelerate Its Growth
- A Great Move By Tilray Brands Doesn't Change The Bigger Picture
- Tilray Brands: Corner Finally Turned (Rating Upgrade)
- Tilray expands cannabis beverage portfolio with Truss Beverage buy
- Tilray's stale marijuana sales prompt beer buying run
- Biggest stock movers today: Medical Properties Trust, Novavax, Eli Lilly, Tilray Brands, and more
- Tilray to buy eight beer brands from Anheuser-Busch in bid to boost beverage portfolio
- Seeking Alpha’s Quant Rating on Tilray
- Earnings data for Tilray
For further details see:
Cannabis stocks rally amid reports DEA may reclassify drug as less risky